Summary & Overview
HCPCS J2280: Injection, Moxifloxacin 100 mg
HCPCS Level II code J2280 represents a 100 mg injection of moxifloxacin, a parenteral fluoroquinolone used for bacterial infections requiring intravenous or intramuscular therapy. Nationally, injectable antibiotic codes such as J2280 matter because they drive reimbursement for drug administration in outpatient infusion centers, clinics, and hospital outpatient departments and can affect access to parenteral therapy options.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for moxifloxacin injections, typical settings where the service is billed, and what information is available for benchmarking and policy considerations. Where input data is limited, the report notes missing elements.
This publication outlines expected service descriptors, common billing modifiers provided in the input, and the potential administrative considerations payers and providers evaluate when processing claims for injectable antimicrobials. It is aimed at billing professionals, policy analysts, and clinicians seeking a clear, national-level summary of the code and its billing context.
Billing Code Overview
HCPCS Level II code J2280 describes an injection of moxifloxacin, 100 mg. The service involves administration of the specified dose of the antibiotic via injection. The service type is medication administration (parenteral anti-infective therapy), and the typical site of service is an outpatient infusion or clinic setting where injectable antibiotics are given.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with a diagnosed severe bacterial corneal ulcer presents to the ophthalmology clinic for intravitreal or periocular antibiotic therapy. The ophthalmologist evaluates visual acuity, performs slit-lamp examination, obtains corneal cultures, and determines that topical therapy alone is insufficient due to deep stromal involvement and risk of rapid progression. After informed discussion, the clinician documents the indication and administers a single injection of moxifloxacin J2280 (100 mg) via the appropriate ocular route in a procedure room. The clinical workflow includes pre-procedure vital signs and allergy check, medication preparation and sterile technique by nursing staff, administration of the injection by the ophthalmologist, post-injection observation for adverse reaction, and documentation of dose, lot number, and site. Billing uses HCPCS Level II code J2280 for the drug supply; appropriate professional service CPT and any applicable modifiers are appended based on the setting, provider role, and circumstances. Typical payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure |